Clinical trial · Observational
sCD8, as a Novel Biomarker for Pancreatic Cancer
The Diagnostic and Survival Predictive Value of Peripheral Serum Soluble CD58 (sCD5858) in Pancreatic Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Early detection and early treatment is the most important issue to improve the long-term survival of pancreatic cancer patients. CA199 is the most commonly used biomarker for early detection and to predict survival, however, the overall positive rate for CA199 is only 75%, and what is worse, for the early stage of pancreatic cancer patients, the positive rate is even lower, and for the lewis negative patients, CA199 is not produced at all. Therefore, novel biomarkers for the early detection of pancreatic cancer are still urgently needed. Previously, we found there is a vicious cycle between pancreatic cancer cells, that is pancreatic cancer-produced TGFbeta1 could promote the production of soluble CD58 (sCD58) in macrophages, and then sCD58 could induce the production of TGFbeta1 in pancreatic cancer cells. Therefore, the serum level of TGFbeta1 and sCD58 has diagnostic and survival values for pancreatic cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
| Serum Biomarker | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| serum test | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (5)
- label
- Pancreatic cancer
- description
- All TNM stages of pancreatic cancer, before/after surgery, before/after chemotherapy, before/after bile drainage
- interventionNames
- Diagnostic Test: serum test
- label
- Low malignant grade of pancreatic neoplasms
- description
- IPMN, MCN, PNEN, and SPN
- interventionNames
- Diagnostic Test: serum test
- label
- Pancreatitis
- description
- acute, chronic, and auto-immune pancreatitis
- interventionNames
- Diagnostic Test: serum test
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Healthy volunteers * Stage I-IV pancreatic cancer patients with pathological diagnosis * Pancreatic cancer patients before and 1 week after surgery * Pancreatic cancer patients before and 1 week after bile drainage * IPMN patients with pathological diagnosis before and 1 week after surgery * MCN patients with pathological diagnosis before and 1 week after surgery * SPN patients with pathological diagnosis before and 1 week after surgery * PNEN patients with pathological diagnosis before and 1 week after surgery * Chronic pancreatitis patients with pathological diagnosis * Cholecystitis patients meeting clinical criteria * Cholangitis patients meeting clinical criteria * Autoimmune diseases meeting clinical criteria Exclusion Criteria: * Refusal to participate * Age less than 18-year old and over 85-year old
References
Publications (2)
- BACKGROUNDZhang Y, Liu Q, Yang S, Liao Q. CD58 Immunobiology at a Glance. Front Immunol. 2021 Jun 8;12:705260. doi: 10.3389/fimmu.2021.705260. eCollection 2021. PMID 34168659
- RESULTZhang Y, Liu Q, Liu J, Liao Q. Upregulated CD58 is associated with clinicopathological characteristics and poor prognosis of patients with pancreatic ductal adenocarcinoma. Cancer Cell Int. 2021 Jun 30;21(1):327. doi: 10.1186/s12935-021-02037-0. PMID 34193136